Adalimumab Persistence for Inflammatory Bowel Disease in Veteran and Insured Cohorts
- 1 December 2018
- journal article
- research article
- Vol. 24 (12) , E374-+
Abstract
OBJECTIVES: Identify predictors of persistence with adalimumab (ADAI among veterans and privately insured patients with inflammatory bowel disease (IBDI in the United States. STUDY DESIGN: Retrospective cohort study. METHODS: Patients with IBD taking ADA as their first biologic were identified from the Veterans Health Administration IVHAI database from 2009 to 2013 and the Truven Health MarketScan database from 2009 to 2012 with a 12 -month follow-up. Persistence was defined as continued use 1 year after initiation. Adherence was assessed by calculating a medication possession ratio, which was dichotomized as greater than 0.86 or less than or equal to 0.86. Multivariable logistic regression was used to evaluate predictors of persistence. RESULTS: There were 1030 patients in the VHA population compared with 3264 patients in the privately insured (MarketScan) cohort. In MarketScan, 1800 patients 155%1 remained on ADA compared with 755 (73%1 in the VHA cohort. In multivariable analysis, male sex (odds ratio [OR], 1.38; 95% CI, 1.16-1.63; P<.011, Crohn disease (OR, 1.27; 95% CI, 1.02-1.57; P=.031, greater adherence (OR, 1.83; 95% CI, 1.45-2.30; P<.011, and dose escalation [OR, 1.82; 95% CI, 1.42-2.33; P<.011 were associated with higher ADA persistence in the MarketScan cohort; narcotic use IOR, 0.71; 95% CI, 0.58-0.88; P<.011 and hospitalization or new steroid use after initiation 10R, 0.04; 95% CI, 0.03-0.05; P<.011 were associated with lower persistence. In the VHA cohort, only a hospitalization or new steroid use (OR, 0.50; 95% CI, 0.36-0.70; P<.01) was associated with lower persistence. CONCLUSIONS: Despite being older and having more comorbidities, patients in the VHA, which is an integrated healthcare system, appear to be more likely to remain on ADA at 1 year than patients in the MarketScan database. Further studies of system differences are needed to understand the reasons behind this discrepancy.Keywords
This publication has 28 references indexed in Scilit:
- Increased risk of herpes zoster among 108 604 patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2012
- Greater refill adherence to adalimumab therapy for patients using specialty versus retail pharmaciesAdvances in Therapy, 2010
- Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapyGut, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literatureClinical, Cosmetic and Investigational Dermatology, 2010
- Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2010
- Update on the incidence and prevalence of Crohnʼs disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000Inflammatory Bowel Diseases, 2007
- Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s diseaseGut, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987